SGMO — Sangamo Therapeutics Share Price
0.000.00%
Last trade - 00:00- $174.99m
- $136.65m
- $57.80m
- 28
- 18
- 42
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.93 | ||
| Price to Tang. Book | 8.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -125.94% | ||
| Return on Equity | -298.41% | ||
| Operating Margin | -76.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 118.19 | 110.7 | 111.3 | 176.23 | 57.8 | 68.7 | 61.32 | -10.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.
Directors
- H. Stewart Parker NEC (65)
- Alexander Macrae PRE (58)
- Prathyusha Duraibabu CFO (43)
- D. Mark McClung EVP (58)
- R. Andrew Ramelmeier EVP (59)
- Jason Fontenot SVP (51)
- Robert Schott SVP (63)
- Robert Carey IND (63)
- Kenneth Hillan IND (60)
- John Markels IND (55)
- James Meyers IND (56)
- Saira Ramasastry IND (45)
- Karen Smith IND (53)
- Joseph Zakrzewski IND
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- June 22nd, 1995
- Public Since
- April 6th, 2000
- No. of Shareholders
- 50
- No. of Employees
- 183
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 301,709,485
- Address
- 501 Canal Blvd., RICHMOND, 94084
- Web
- https://www.sangamo.com/
- Phone
- +1 5109706000
- Contact
- Louise Wilkie
- Auditors
- Ernst & Young LLP
Upcoming Events for SGMO
Similar to SGMO
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Sangamo Therapeutics share price?
As of Today at 23:03 UTC, shares in Sangamo Therapeutics are trading at $0.58. This share price information is delayed by 15 minutes.
How has the Sangamo Therapeutics share price performed this year?
Shares in Sangamo Therapeutics last closed at $0.58 and the price had moved by -34.83% over the past 365 days. In terms of relative price strength the Sangamo Therapeutics share price has underperformed the S&P500 Index by -43.88% over the past year.
What are the analyst and broker recommendations for Sangamo Therapeutics?
The overall consensus recommendation for Sangamo Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sangamo Therapeutics dividend yield?
Sangamo Therapeutics does not currently pay a dividend.
Does Sangamo Therapeutics pay a dividend?
Sangamo Therapeutics does not currently pay a dividend.
When does Sangamo Therapeutics next pay dividends?
Sangamo Therapeutics does not currently pay a dividend.
How do I buy Sangamo Therapeutics shares?
To buy shares in Sangamo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sangamo Therapeutics?
As of the previous close price of $0.58, shares in Sangamo Therapeutics had a market capitalisation of $174.99m.
Where are Sangamo Therapeutics shares listed?
Here are the trading details for Sangamo Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SGMO
What kind of share is Sangamo Therapeutics?
Based on an overall assessment of its quality, value and momentum Sangamo Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sangamo Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Sangamo Therapeutics is $4.10. That is 606.9% above the last closing price of $0.58.
Analysts covering Sangamo Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.30 for the next financial year.
Find out moreWhat is the trend in the Sangamo Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sangamo Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -52.89%.
As of the last closing price of $0.58, shares in Sangamo Therapeutics were trading -46.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sangamo Therapeutics PE Ratio?
The Sangamo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sangamo Therapeutics?
Sangamo Therapeutics' management team is headed by:
- H. Stewart Parker - NEC
- Alexander Macrae - PRE
- Prathyusha Duraibabu - CFO
- D. Mark McClung - EVP
- R. Andrew Ramelmeier - EVP
- Jason Fontenot - SVP
- Robert Schott - SVP
- Robert Carey - IND
- Kenneth Hillan - IND
- John Markels - IND
- James Meyers - IND
- Saira Ramasastry - IND
- Karen Smith - IND
- Joseph Zakrzewski - IND